Combination of trastuzumab and pertuzumab disrupted the heterodimerization of HER2 with HER3, inhibited AKT signaling in BT-474, and suppressed HER2-positive breast and non-small cell lung cancer xenografts more potently than either monotherapy (49, 50). Here, ERBB3 is linked to non-small cell lung carcinoma.